Cargando…
Epigenetic cancer therapy /
Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-maker...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Elsevier : Academic Press,
[2015]
|
| Colección: | Translational epigenetics series.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn913208366 | ||
| 003 | OCoLC | ||
| 005 | 20231120112006.0 | ||
| 006 | m o d u | ||
| 007 | cr ||||||||||| | ||
| 008 | 150706s2015 ne ob 001 0 eng d | ||
| 040 | |a NLGGC |b eng |e rda |e pn |c NLGGC |d N$T |d OPELS |d N$T |d YDXCP |d EBLCP |d COO |d IDEBK |d CDX |d DEBSZ |d OCLCF |d PUL |d FEM |d RTH |d YDX |d U3G |d OCLCO |d OCLCQ |d MERER |d OCLCQ |d CASUM |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d MERUC |d OCLCO |d OCLCQ |d OCLCO |d U3W |d OCLCO |d D6H |d OCLCO |d OCLCQ |d CHVBK |d OCLCQ |d OCLCO |d OCLCQ |d WYU |d OCLCO |d OCLCA |d OCLCQ |d WURST |d S2H |d OCLCO |d VT2 |d OCLCO |d OCLCQ |d KGN |d OCLCQ |d OCLCO | ||
| 016 | 7 | |a 101674257 |2 DNLM | |
| 019 | |a 913695384 |a 962048319 |a 968087756 |a 1066420821 |a 1235841751 | ||
| 020 | |a 9780128002247 |q (electronic bk.) | ||
| 020 | |a 0128002247 |q (electronic bk.) | ||
| 020 | |z 9780128002063 | ||
| 020 | |z 0128002069 | ||
| 035 | |a (OCoLC)913208366 |z (OCoLC)913695384 |z (OCoLC)962048319 |z (OCoLC)968087756 |z (OCoLC)1066420821 |z (OCoLC)1235841751 | ||
| 050 | 4 | |a RC271.G45 | |
| 060 | 4 | |a QZ 266 | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.99/40695 |2 23 |
| 245 | 0 | 0 | |a Epigenetic cancer therapy / |c edited by Steven G. Gray. |
| 264 | 1 | |a Amsterdam : |b Elsevier : |b Academic Press, |c [2015] | |
| 264 | 4 | |c �2015 | |
| 300 | |a 1 online resource (xxvi, 721 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file | ||
| 490 | 1 | |a Translational epigenetics series | |
| 500 | |a Includes index. | ||
| 500 | |a Academic Press is an imprint of Elsevier. | ||
| 505 | 0 | |a Front Cover; Epigenetic Cancer Therapy; Copyright Page; Contents; List of Contributors; 1 Introduction; 1 Introduction to the Area (Key Concepts); 2 Epigenetics and Cancer; 3 Targeting Aberrant Epigenetics; 4 Issues to Overcome/Areas of Concern; 5 Future Directions: Translation to the Clinic; References; 1 Introduction and Key Concepts; 2 DNA Methylation and Hydroxymethylation in Cancer; 1 Introduction; 2 Epigenetics; 2.1 Chromatin Structure; 2.2 DNA Methylation in Cellular Homeostasis; 2.2.1 Genomic distribution of DNA methylation; 2.2.2 Functional role of DNA methylation. | |
| 505 | 8 | |a 2.2.3 DNA methyltransferases2.2.4 Recruitment of DNMTs; 2.3 DNA Demethylation; 3 DNA Methylation Patterns in Cancer; 3.1 Hypermethylation in Cancer; 3.2 Hypomethylation in Cancer; 3.3 Methods for 5mC Detection; 4 Aberrations of Enzymes Involved in DNA Methylation Homeostasis in Cancer; 4.1 DNA Methyltransferase; 4.2 TET Proteins; 4.3 Isocitrate Dehydrogenases; 4.4 Succinate Dehydrogenases; 5 DNA Hydroxymethylation in Cancer; 5.1 Methods for 5hmC Detection; 5.1.1 Affinity-based enrichment approach; 5.1.2 Chemical methods; 5.1.3 Quantitative methods at single base resolution. | |
| 505 | 8 | |a 5.1.4 Third-generation sequencing5.2 DNA Hydroxymethylation Patterns in Cancer; 6 Conclusion; References; 3 Writers, Readers, and Erasers of Epigenetic Marks; 1 Introduction; 2 Writers; 2.1 DNA Methyltransferases; 2.2 Histone Lysine Methyltransferases; 2.3 Protein Arginine Methyltransferases; 2.4 Histone Acetyltransferases; 3 Readers; 3.1 Methyl-CpG-Binding Proteins; 3.2 Histone Methylation-Binding Domains; 3.3 Histone Acetylation-Binding Domains; 4 Erasers; 4.1 Proteins Involved in DNA Demethylation; 4.2 Histone Demethylases; 4.3 Histone Deacetylases (HDACs). | |
| 505 | 8 | |a 5 Interactions between the Various Components6 Epigenetics and Cancer; 6.1 DNA Methylation and Cancer; 6.2 Histone Methylation and Cancer; 6.3 Histone Acetylation and Cancer; 7 Epigenetic Proteins as Therapeutic Targets; 8 Conclusion and Future Opportunities; References; 4 MicroRNAs and Cancer; 1 miRNA Biogenesis and Functionality; 2 miRNAs in Cancer Biology; 3 miRNA: An Epigenetic Perspective; 3.1 Epigenetic Alteration of miRNA Expression; 3.2 Epi-miRNA; 3.3 miRNA with Epigenetic Functions; 4 miRNA Epigenetic Therapy; 4.1 miRNA Inhibition in Cancer; 4.2 miRNA Replacement in Cancer. | |
| 505 | 8 | |a 4.3 Small-Molecule-Based miRNA Modulation5 Future Perspectives; Acknowledgments; References; 5 Long Noncoding RNAs and Cancer; 1 Introduction; 2 Classification and Nomenclature of lncRNAs; 2.1 Classification; 2.2 Nomenclature; 3 Mechanisms of lncRNA Function; 3.1 lncRNAs as Decoys and Guides; 3.2 lncRNAs as Scaffolds; 3.3 lncRNAs as Signaling Molecules; 3.4 miRNA Sequestration; 3.5 lncRNAs and Epigenetic Regulation; 3.5.1 H19; 3.5.2 AIR and KCNQ1OT1; 3.5.3 lincRNAs; 4 lncRNAs and Human Disease; 4.1 Prognostic Markers; 4.1.1 lncRNAs in the circulation. | |
| 520 | |a Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector. The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver). The bo. | ||
| 504 | |a Includes bibliographical references at the end of each chapters and index. | ||
| 650 | 0 | |a Cancer |x Gene therapy. | |
| 650 | 0 | |a Epigenetics. | |
| 650 | 1 | 2 | |a Neoplasms |x genetics |0 (DNLM)D009369Q000235 |
| 650 | 2 | 2 | |a Epigenesis, Genetic |0 (DNLM)D044127 |
| 650 | 6 | |a Cancer |x Th�erapie g�enique. |0 (CaQQLa)201-0241421 | |
| 650 | 6 | |a �Epig�en�etique. |0 (CaQQLa)000270630 | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Cancer |x Gene therapy |2 fast |0 (OCoLC)fst00845367 | |
| 650 | 7 | |a Epigenetics |2 fast |0 (OCoLC)fst01893642 | |
| 653 | 0 | 0 | |a oncologie |
| 653 | 0 | 0 | |a oncology |
| 653 | 0 | 0 | |a neoplasma |
| 653 | 0 | 0 | |a neoplasms |
| 653 | 0 | 0 | |a therapie |
| 653 | 0 | 0 | |a therapy |
| 653 | 0 | 0 | |a epigenetica |
| 653 | 0 | 0 | |a epigenetics |
| 653 | 1 | 0 | |a Medicine (General) |
| 653 | 1 | 0 | |a Geneeskunde (algemeen) |
| 655 | 4 | |a Internet Resources. | |
| 700 | 1 | |a Gray, Steven G., |e editor. | |
| 776 | 0 | 8 | |i Print version: |a Gray, Steven. |t Epigenetic Cancer Therapy. |d Burlington : Elsevier Science, �2015 |z 9780128002063 |
| 830 | 0 | |a Translational epigenetics series. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780128002063 |z Texto completo |